BlackRock Advisors’s Protalix BioTherapeutics PLX Stock Holding History

BlackRock Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-164,523	Closed	-$2.93M	–	3733
2015 Q1	$2.93M	Hold	164,523	–	–	﹤0.01%	1098
2014 Q4	$3.03M	Sell	164,523 -5,675	-3%	-$122K	﹤0.01%	1080
2014 Q3	$4.12M	Sell	170,198 -9,238	-5%	-$266K	﹤0.01%	1016
2014 Q2	$6.55M	Buy	179,436 +161	+0.1%	+$6.49K	0.01%	901
2014 Q1	$8.21M	Hold	179,275	–	–	0.01%	856
2013 Q4	$6.97M	Sell	179,275 -36,706	-17%	-$1.55M	0.01%	911
2013 Q3	$9.78M	Buy	215,981 +31,420	+17%	+$1.61M	0.01%	797
2013 Q2	$9.06M	Buy	+184,561	New	+$9.79M	0.01%	810

Other funds holding PLX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MTWSIF

Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

BlackRock Advisors's PLX Position: Q2 2015 in Review

BlackRock Advisors sold out of Protalix BioTherapeutics (PLX) in Q2 2015, closing a stake of 164,523 shares — an estimated $2.93M sold.

BlackRock Advisors first reported a position in PLX in Q2 2013 and held it in 8 quarters. The position peaked at $9.78M in Q3 2013. 35 funds tracked by Wall St. Rank hold PLX as of Q2 2015.

BlackRock Advisors reported no remaining Protalix BioTherapeutics position as of Q2 2015 after selling out during the quarter.
BlackRock Advisors sold 164,523 Protalix BioTherapeutics shares in Q2 2015, an estimated $2.93M.
BlackRock Advisors first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 8 quarters.
BlackRock Advisors's Protalix BioTherapeutics position peaked at $9.78M in Q3 2013.
35 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2015.

Based on BlackRock Advisors's 13F filing for Q2 2015, filed 7 Aug 2015.